Rosiglitazone is not associated with an increased risk of bladder cancer

Cancer Epidemiology

Volumn 37, Issue 4, 2013, Pages 385-389

  Tseng, Chin Hsiao ^a,b  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

Author keywords

Bladder cancer; Diabetes mellitus; Pioglitazone; Rosiglitazone; Taiwan

Indexed keywords

ACARBOSE; ANGIOTENSIN RECEPTOR ANTAGONIST; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; MEGLITINIDE; METFORMIN; NONSTEROID ANTIINFLAMMATORY AGENT; ORAL ANTIDIABETIC AGENT; ROSIGLITAZONE; SULFONYLUREA;

ADULT; AGED; ARTICLE; BLADDER CANCER; CANCER INCIDENCE; CANCER RISK; CONTROLLED STUDY; DIABETIC PATIENT; DOSE RESPONSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; TAIWAN; TREATMENT DURATION;

ADULT; AGED; DATABASES, FACTUAL; DIABETES MELLITUS, TYPE 2; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPOGLYCEMIC AGENTS; INCIDENCE; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; REGRESSION ANALYSIS; TAIWAN; THIAZOLIDINEDIONES; TIME FACTORS; URINARY BLADDER NEOPLASMS;

EID: 84878931167     PISSN: 18777821     EISSN: 1877783X     Source Type: Journal    
DOI: 10.1016/j.canep.2013.03.013     Document Type: Article

References (32)

1. Wotton C.J., Yeates D.G., Goldacre M.J. Cancer in patients admitted to hospital with diabetes mellitus aged 30 years and over: record linkage studies. Diabetologia 2011, 54:527-534.
2. Li C., Balluz L.S., Ford E.S., Okoro C.A., Tsai J., Zhao G. Association between diagnosed diabetes and self-reported cancer among U.S. adults: findings from the 2009 Behavioral Risk Factor Surveillance System. Diabetes Care 2011, 34:1365-1368.
3. Tseng C.H., Chong C.K., Tai T.Y. Secular trend for mortality from breast cancer and the association between diabetes and breast cancer in Taiwan between 1995 and 2006. Diabetologia 2009, 52:240-246.
4. Tseng C.H. Diabetes conveys a higher risk of gastric cancer mortality despite an age-standardised decreasing trend in the general population in Taiwan. Gut 2011, 60:774-779.
5. Tseng C.H. Diabetes and risk of bladder cancer: a study using the National Health Insurance database in Taiwan. Diabetologia 2011, 54:2009-2015.
6. Woolcott C.G., Maskarinec G., Haiman C.A., Henderson B.E., Kolonel L.N. Diabetes and urothelial cancer risk: the Multiethnic Cohort study. Cancer Epidemiol 2011, 35:551-554.
7. Tseng C.H. Diabetes and non-Hodgkin's lymphoma: analyses of prevalence and annual incidence in 2005 using the National Health Insurance database in Taiwan. Ann Oncol 2012, 23:153-158.
8. Tseng C.H. Diabetes, insulin use, and non-Hodgkin lymphoma mortality in Taiwan. Metabolism 2012, 61:1003-1009.
9. Giovannucci E., Harlan D.M., Archer M.C., Bergenstal R.M., Gapstur S.M., Habel L.A., et al. Diabetes and cancer: a consensus report. Diabetes Care 2010, 33:1674-1685.
10. Sanderson M., Peltz G., Perez A., Johnson M., Vernon S.W., Fernandez M.E., et al. Diabetes, physical activity and breast cancer among Hispanic women. Cancer Epidemiol 2010, 34:556-561.
11. Hitron A., Adams V., Talbert J., Steinke D. The influence of antidiabetic medications on the development and progression of prostate cancer. Cancer Epidemiol 2012, 36:e243-e250.
12. Dong X., Li Y., Tang H., Chang P., Hess K.R., Abbruzzese J.L., et al. Insulin-like growth factor axis gene polymorphisms modify risk of pancreatic cancer. Cancer Epidemiol 2012, 36:206-211.
13. Hammarsten J., Damber J.E., Peeker R., Mellström D., Högstedt B. A higher prediagnostic insulin level is a prospective risk factor for incident prostate cancer. Cancer Epidemiol 2010, 34:574-579.
14. Zhang Z.J., Zheng Z.J., Kan H., Song Y., Cui W., Zhao G., et al. Reduced risk of colorectal cancer with metformin therapy in patients with type 2 diabetes: a meta-analysis. Diabetes Care 2011, 34:2323-2328.
15. Blin P., Lassalle R., Dureau-Pournin C., Ambrosino B., Bernard M.A., Abouelfath A., et al. Insulin glargine and risk of cancer: a cohort study in the French National Healthcare Insurance Database. Diabetologia 2012, 55:644-653.
16. Dormandy J.A., Charbonnel B., Eckland D.J., Erdmann E., Massi-Benedetti M., Moules I.K., et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005, 366:1279-1289.
17. Tseng C.H. Pioglitazone and bladder cancer in human studies: is it diabetes itself, diabetes drugs, flawed analyses or different ethnicities?. J Formos Med Assoc 2012, 111:123-131.
18. Lewis J.D., Ferrara A., Peng T., Hedderson M., Bilker W.B., Quesenberry C.P., et al. Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study. Diabetes Care 2011, 34:916-922.
19. Neumann A., Weill A., Ricordeau P., Fagot J.P., Alla F., Allemand H. Pioglitazone and risk of bladder cancer among diabetic patients in France: a population-based cohort study. Diabetologia 2012, 55:1953-1962.
20. Tseng C.H. Pioglitazone and bladder cancer: a population-based study of Taiwanese. Diabetes Care 2012, 35:278-280.
21. Yang X., Chan J.C. Comment: analyses using time-dependent pioglitazone usage in Cox models may lead to wrong conclusions about its association with cancer. Diabetes Care 2011, 34:e136.
22. Nissen S.E., Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007, 356:2457-2471.
23. Tseng C.H. Diabetes and risk of prostate cancer: a study using the National Health Insurance. Diabetes Care 2011, 34:616-621.
24. Tseng C.H., Tseng F.H. Peroxisome proliferator-activated receptor agonists and bladder cancer: lessons from animal studies. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev 2012, 30:368-402.
25. Jacobs B.L., Lee C.T., Montie J.E. Bladder cancer in 2010: how far have we come?. CA Cancer J Clin 2010, 60:244-272.
26. van Stralen K.J., Dekker F.W., Zoccali C., Jager K.J. Confounding. Nephron Clin Pract 2010, 116:143-714.
27. Goldberg R.B., Kendall D.M., Deeg M.A., Buse J.B., Zagar A.J., Pinaire J.A., et al. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care 2005, 28:1547-1554.
28. Kahn S.E., Haffner S.M., Heise M.A., Herman W.H., Holman R.R., Jones N.P., et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006, 355:2427-2443.
29. European Medicines Agency. European Medicines Agency recommends suspension of Avandia, Avandamet and Avaglim. [accessed 25.02.12]. http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2010/09/news_detail_001119.jsp&murl=menus/news_and_events/news_and_events.jsp&mid=WC0b01ac058004d5c1&jsenabled=false.
30. Shah N.D., Montori V.M., Krumholz H.M., Tu K., Alexander G.C., Jackevicius C.A. Responding to an FDA warning-geographic variation in the use of rosiglitazone. N Engl J Med 2010, 363:2081-2084.
31. Fu C.C., Chang C.J., Tseng C.H., Chen M.S., Kao C.S., Wu T.J., et al. Development of macrovascular diseases in non-insulin-dependent-diabetics in northern Taiwan: a four-year follow-up study. Diabetes Care 1993, 16:137-143.
32. Cheng T.M. Taiwan's new national health insurance program: genesis and experience so far. Health Aff (Millwood) 2003, 22:61-76.